ข่าวประชาสัมพันธ์the Marketing | newswit
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting – Elacestrant has been approved by the FDA for treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine
TerraPay raises $100 million in series B funding to expand global payments infrastructure – The funding will help further TerraPay's global expansion plans, especially across the LATAM and MENA regions, strengthen its existing pay-out network to 150 countries by 2024, support and accelerate its growth, and invest in the marketing and adoption of alternate payment methods for mobile wallets, like Request-to-Pay - an
Grand Seiko Opens Its First Boutique in Singapore at Marina Bay Sands – Grand Seiko Boutique Singapore Marina Bay Sands:https://kyodonewsprwire.jp/prwfile/release/M102037/202302243243/_prw_PI3fl_1wp0fU3U.jpgIn the presence of H.E. Hiroshi Ishikawa, Ambassador Extraordinary and Plenipotentiary of Japan to Singapore, Grand Seiko officially opened the 134-square-meter boutique's doors in a grand ceremony. In addition to the
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO(R) (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Mult – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe – Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP) has decided to shift its assessment of the Marketing Authorisation Application (MAA) for leniolisib to a standard review timetable. Leniolisib is an
